#USA #Genomics #MyOme #MsMedicine #Menlo Park, Cincinnati

MyOme and Ms.Medicine Unite for Revolutionary Primary Care

In a groundbreaking collaboration, MyOme, a prominent clinical whole-genome testing and polygenic risk modelling company, has joined forces with Ms.Medicine, a leading national network of women's health practices. This partnership aims to redefine primary care by integrating genomic insights into everyday medical practices, elevating the standard of care for women.

A New Era in Patient Care

The essence of this strategic alliance lies in the introduction of MyOme's Proactive Health portfolio, a comprehensive solution that fuses monogenic disease screening, pharmacogenomic insights, and integrated polygenic risk scores. By doing so, clinicians can better identify genetic risks, personalize prevention strategies, and tailor treatment throughout a woman’s lifespan.

One significant advantage of this collaboration is for women with a familial history of diseases such as breast cancer. Now, as part of their routine check-ups, they can undergo genomic testing. MyOme’s integrated report enables healthcare providers to evaluate both rare (monogenic) and common (polygenic) genetic risks, decide on necessary enhanced screenings, and utilize pharmacogenomic data to inform medication choices.

Benefits to Both Patients and Clinicians

Dr. Premal Shah, CEO of MyOme, emphasized the importance of embedding genomic insights into routine primary care. He stated, "This collaboration brings genomics into routine primary care where it can have the greatest impact." By facilitating earlier identification of risks, healthcare professionals can guide patients toward standard-of-care interventions timely, which is crucial for preventing, delaying, or catching diseases early while minimizing treatment costs and maximizing effectiveness.

For Ms.Medicine, the partnership aligns perfectly with its mission to reduce the gender disparity in healthcare. Dr. Lisa Larkin, CEO of Ms.Medicine, shared, "Our mission has always been to elevate the standard-of-care by making it individualized, evidence-based, and proactive." With the integration of MyOme's genomic testing, clinicians are empowered to administer precision medicine during routine visits. This approach allows women to recognize their health risks earlier and make informed decisions to mitigate potential diseases.

Transformational Technology

The implementation of MyOme’s tests is supported by an existing collaboration with Nest Genomics, a clinical decision-support platform that streamlines the integration of genomic insights into Electronic Health Records (EHR). This seamless incorporation allows clinicians to efficiently order genetic testing while interpreting and acting on genetic information precisely when it matters — at the point of care. The result is a significant transformation of complex genomic data into actionable medical insights that patients encounter regularly.

The Blueprint for the Future

The MyOme and Ms.Medicine partnership is poised to serve as a model for how genomics-informed care can be operationalized within primary care programs and women’s health initiatives across the nation. Their combined efforts in whole-genome sequencing, disease risk assessment, and pharmacogenomics are not just innovative but pivotal in creating a unified approach for preventative and proactive health management.

Conclusion

With a shared commitment to enhancing patient care through genomic insights, MyOme and Ms.Medicine are paving the way for a healthier future for women. This partnership signifies a movement toward a more personalized healthcare landscape where genomics plays a central role in evaluating, preventing, and managing health risks effectively.

For more information about MyOme, visit www.myome.com and for Ms.Medicine, check out www.msmedicine.com.